Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations

29 Mar 2015

Abstract excerpt

Reversal of HIV-1 latency by small molecules is a potential cure strategy. This approach will likely require effective drug combinations to achieve high levels of latency reversal. Using resting CD4+ T cells (rCD4s) from infected individuals, we developed an experimental and theoretical framework to identify effective latency-reversing agent (LRA) combinations. Utilizing ex vivo assays for intracellular HIV-1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV/AIDS Research and Interventions
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25822022
DOI: 10.1172/jci80142

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinationsPMID 25822022Read ↗

Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agentsSemantic proximity Read ↗

Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoirSemantic proximity Read ↗

The role of latency reversal in HIV cure strategiesSemantic proximity Read ↗

Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing AgentsSemantic proximity Read ↗

Curing HIV: Pharmacologic Approaches to Target HIV-1 LatencySemantic proximity Read ↗

Breaking the Silence: Regulation of HIV Transcription and Latency on the Road to a CureSemantic proximity Read ↗

The Current Status of Latency Reversing Agents for HIV-1 RemissionSemantic proximity Read ↗

Precision Elimination: Proof-of-Concept In Silico Testing of a Novel Construct for Optimizing HIV-1 EradicationSemantic proximity Read ↗

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene ExpressionSemantic proximity Read ↗

Therapeutics for HIV-1 reactivation from latencySemantic proximity Read ↗

Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue ReservoirsSemantic proximity Read ↗

HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency StudiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.